Breaking News

Tiziana Partners with Renaissance Lakewood to Scale Up Foralumab

Renaissance will optimize the formulation of intranasal Foralumab and assist with scaling up production for clinical trials.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Tiziana Life Sciences Ltd., a clinical-stage biotechnology company, entered an agreement with Renaissance Lakewood LLC, a CDMO, to advance the development intra-nasal drug candidate Foralumab. Foralumab, a biologic drug candidate, is Tiziana’s fully human anti-CD3 monoclonal antibody in development for neurodegenerative and inflammatory diseases. Under the agreement, Renaissance will use its expertise in nasal drug delivery to optimize the formulation of intranasal Foralumab and assi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters